Condition: Epithelial Tumors, Malignant · Sponsor: Myeloid Therapeutics
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
This description comes directly from the study's public registry record.
Shinam Garg · +61 2 9171 3260 · Shinam.garg@novotech-cro.com
Clinical Operations · +1 617 465 1022 · mt-302clinical@myeloidtx.com
Always discuss trial participation with your own doctor first.
| St Vincent's Public Hospital Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Souther Oncology Clinical Research Unit (SOCRU) | Bedford Park, South Australia, Australia | Recruiting |
| Cabrini Health | Malvern, Victoria, Australia | Recruiting |
| Linear Clinical Research Ltd | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05969041